Get the Stockscreener App
10.59
11.01%
-1.31
Actuate Therapeutics Inc stock is traded at $10.59, with a volume of 172.10K.
It is down -11.01% in the last 24 hours and up +0.57% over the past month.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
See More
Previous Close:
$11.90
Open:
$11.7
24h Volume:
172.10K
Relative Volume:
3.12
Market Cap:
$207.78M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.52%
1M Performance:
+0.57%
6M Performance:
+18.72%
1Y Performance:
+0.00%
1-Day Range:
$9.3584
$11.70
1-Week Range:
$9.3584
$11.99
52-Week Range:
$5.51
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Name
Actuate Therapeutics Inc
Sector
Industry
Phone
847-986-4190
Address
1751 RIVER RUN, FORT WORTH
Compare ACTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
10.59 | 202.28M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Craig Hallum | Buy |
| Mar-17-25 | Initiated | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Stock (ACTU) Latest News
Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib - TipRanks
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - Barchart.com
Actuate Therapeutics Shares Highlights from KOL Event on - GlobeNewswire
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - Yahoo Finance
Actuate Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - MENAFN.com
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - Insider Monkey
Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer (ACTU:NASDAQ) - Seeking Alpha
Actuate Therapeutics Presents Topline Elraglusib Phase 2 - GlobeNewswire
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire Inc.
P2P Group And NATO Registered Partner Aliter Showcases Inturai Stealthwave Video - The Globe and Mail
Actuate Therapeutics Elects Directors at Annual Meeting - TipRanks
Actuate Therapeutics Reports Phase 2 Trial Success Showing Improved Survival in Metastatic Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Details for 2025 ASCO Annual - GlobeNewswire
BIOS Capital Management LP Takes $78.75 Million Position in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Shares in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Apple Is Threatening to Challenge Alphabet's Empire: Is the Stock a Buy? - The Globe and Mail
Adding elraglusib seen to improve survival in pancreatic cancer trial - Rare Cancer News
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President - The Manila Times
Envestnet Asset Management Inc. Invests $83,000 in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Managing Adverse Events in Pembrolizumab Therapy for Gastric Cancer - Targeted Oncology
Actuate jumps as lead drug succeeds in mid-stage trial for pancreatic cancer - MSN
Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial - BioWorld MedTech
Actuate Therapeutics to Host KOL Event on Topline Phase 2 - GlobeNewswire
Actuate Therapeutics to host KOL event on Phase 2 elraglusib data - TipRanks
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting - Yahoo Finance
PTC hits Huntington biomarker, but approval path still uncertain - BioCentury
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data - Endpoints News
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Actuate stock jumps after cancer trial data (ACTU:NASDAQ) - Seeking Alpha
Elraglusib shows survival benefit in pancreatic cancer trial - Investing.com Australia
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Elraglusib shows survival benefit in pancreatic cancer trial By Investing.com - Investing.com South Africa
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
Why Are Young Adults Getting More Pancreatic & Colon Cancer? - Targeted Oncology
Younger Adults See Sharp Rise in Pancreas & Colon Cancer, Study Shows - Targeted Oncology
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Actuate Therapeutics to Present Topline Phase 2 Data of Elraglusib at 2025 ASCO Annual Meeting - Nasdaq
Actuate to Present Elraglusib Phase 2 Topline Data at the - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at Craig Hallum - Defense World
Craig-Hallum sets $21 target on Actuate Therapeutics stock By Investing.com - Investing.com Canada
3 No-Brainer Artificial Intelligence (AI) Stocks to Buy Before Earnings Season Heats Up - The Globe and Mail
What Will Actuate Therapeutics Inc (NASDAQ: ACTU) Be Like In 2025 - stocksregister.com
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Actuate Therapeutics to Present Elraglusib Data for Advanced Salivary Gland Carcinoma at AACR Annual Meeting 2025 - Nasdaq
Actuate to Present Promising Data on Elraglusib in Advanced - GlobeNewswire
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 - Yahoo Finance
Disparities in Treatment/Survival Outcomes Observed in Metastatic PDAC - CancerNetwork
Actuate Therapeutics Inc Stock (ACTU) Financials Data
There is no financial data for Actuate Therapeutics Inc (ACTU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):